Wave Life Sciences (WVE) Stock Forecast & Price Target

Compare

949 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

WVE Analyst Ratings

Strong Buy

13 Buy

1 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Wave

Life Sciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

WVE Stock 12 Month Forecast

Average Price Target

$18.23

▲(154.61% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Wave Life Sciences in the last 3 months. The average price target is $18.23 with a high forecast of $26.00 and a low forecast of $9.00. The average price target represents a 154.61% change from the last price of $7.16.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","27":"$27","9.75":"$9.75","15.5":"$15.5","21.25":"$21.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$26.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$18.23</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,9.75,15.5,21.25,27],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.62,10.879999999999999,12.14,13.4,14.66,15.92,17.18,18.44,19.700000000000003,20.96,22.22,23.480000000000004,24.740000000000002,{"y":26,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.62,10.282307692307691,10.944615384615384,11.606923076923076,12.269230769230768,12.93153846153846,13.593846153846155,14.256153846153847,14.918461538461539,15.580769230769231,16.243076923076924,16.905384615384616,17.567692307692308,{"y":18.23,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.62,9.572307692307692,9.524615384615384,9.476923076923077,9.429230769230768,9.381538461538462,9.333846153846153,9.286153846153846,9.238461538461538,9.19076923076923,9.143076923076922,9.095384615384615,9.047692307692309,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.74,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.3,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.83,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.27,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.37,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.57,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.57,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.74,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.94,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.25,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.52,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.63,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.62,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$26.00

Average Price Target$18.23

Lowest Price Target$9.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Joon Lee

Truist Financial

―

Buy

―

Reiterated

09/04/25

Truist Financial Reaffirms Their Buy Rating on Wave Life Sciences (WVE)

Joseph Schwartz

Leerink Partners

$24→$26

Buy

263.13%

Upside

Reiterated

09/04/25

Wave Life Sciences price target raised to $26 from $24 at LeerinkWave Life Sciences price target raised to $26 from $24 at Leerink

Whitney Ijem

Canaccord Genuity

$19

Buy

165.36%

Upside

Reiterated

09/04/25

Wave Life Sciences: Strong Buy Rating Backed by Promising WVE-006 Trial Results and Strategic GSK Partnership

Tiago Fauth

Wells Fargo

$21→$18

Buy

151.40%

Upside

Reiterated

09/04/25

Wave Life Sciences price target lowered to $18 from $21 at Wells FargoWave Life Sciences price target lowered to $18 from $21 at Wells Fargo

Madison Elsaadi

B.Riley Financial

$19

Buy

165.36%

Upside

Reiterated

09/04/25

B. Riley 'aggressive' buyer of Wave Life on 'material disconnect'B. Riley 'aggressive' buyer of Wave Life on 'material disconnect'

Andrew Fein

H.C. Wainwright

$22

Buy

207.26%

Upside

Reiterated

09/03/25

Promising Prospects for Wave Life Sciences: Fein's Buy Rating Backed by WVE-006 Data and Strategic Partnerships

Catherine Novack

JonesTrading

$20

Buy

179.33%

Upside

Reiterated

09/03/25

Promising Potential in Wave Life Sciences' RNA Editing Technology Justifies Buy Rating Despite Modest Dose Response

Michael W. Freeman

Raymond James

$14

Buy

95.53%

Upside

Reiterated

09/03/25

Raymond James Reaffirms Their Buy Rating on Wave Life Sciences (WVE)Raymond James analyst Michael Freeman reiterated an Outperform rating and $14.00 price target on WAVE Life Sciences (NASDAQ: WVE).

Yun Zhong

Wedbush

$18

Buy

151.40%

Upside

Reiterated

09/03/25

Optimistic Buy Rating for Wave Life Sciences Driven by Promising RNA Editing Technology and Strong Safety Profile

Salim Syed

Mizuho Securities

$22

Buy

207.26%

Upside

Reiterated

08/04/25

Mizuho Securities Reaffirms Their Buy Rating on Wave Life Sciences (WVE)WVE (OP, maintaining PT at $22): No major changes to our model.

Cheng Li

Oppenheimer

$24

Buy

235.20%

Upside

Initiated

07/31/25

Wave Life Sciences initiated with an Outperform at OppenheimerWave Life Sciences initiated with an Outperform at Oppenheimer

Luca Issi

RBC Capital

Hold

25.70%

Upside

Reiterated

07/30/25

Analysts Offer Insights on Healthcare Companies: Dexcom (NASDAQ: DXCM), ADC Therapeutics (NYSE: ADCT) and Wave Life Sciences (NASDAQ: WVE)

Samantha Semenkow

Citi

$16

Buy

123.46%

Upside

Initiated

07/17/25

Wave Life Sciences: Promising RNA Therapies and Strong Financial Position Support Buy Rating

Steven Seedhouse

Cantor Fitzgerald

$10

Buy

39.66%

Upside

Reiterated

07/11/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Wave Life Sciences (WVE)

Roger Song

Jefferies

$26

Buy

263.13%

Upside

Reiterated

03/26/25

Jefferies reiterates Buy Rating on WAVE Life Sciences (WVE)Jefferies analyst Roger Song reiterated a Buy rating and $26.00 price target on WAVE Life Sciences (NASDAQ: WVE).

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Joon Lee

Truist Financial

―

Buy

―

Reiterated

09/04/25

Truist Financial Reaffirms Their Buy Rating on Wave Life Sciences (WVE)

Joseph Schwartz

Leerink Partners

$24→$26

Buy

263.13%

Upside

Reiterated

09/04/25

Wave Life Sciences price target raised to $26 from $24 at LeerinkWave Life Sciences price target raised to $26 from $24 at Leerink

Whitney Ijem

Canaccord Genuity

$19

Buy

165.36%

Upside

Reiterated

09/04/25

Wave Life Sciences: Strong Buy Rating Backed by Promising WVE-006 Trial Results and Strategic GSK Partnership

Tiago Fauth

Wells Fargo

$21→$18

Buy

151.40%

Upside

Reiterated

09/04/25

Wave Life Sciences price target lowered to $18 from $21 at Wells FargoWave Life Sciences price target lowered to $18 from $21 at Wells Fargo

Madison Elsaadi

B.Riley Financial

$19

Buy

165.36%

Upside

Reiterated

09/04/25

B. Riley 'aggressive' buyer of Wave Life on 'material disconnect'B. Riley 'aggressive' buyer of Wave Life on 'material disconnect'

Andrew Fein

H.C. Wainwright

$22

Buy

207.26%

Upside

Reiterated

09/03/25

Promising Prospects for Wave Life Sciences: Fein's Buy Rating Backed by WVE-006 Data and Strategic Partnerships

Catherine Novack

JonesTrading

$20

Buy

179.33%

Upside

Reiterated

09/03/25

Promising Potential in Wave Life Sciences' RNA Editing Technology Justifies Buy Rating Despite Modest Dose Response

Michael W. Freeman

Raymond James

$14

Buy

95.53%

Upside

Reiterated

09/03/25

Raymond James Reaffirms Their Buy Rating on Wave Life Sciences (WVE)Raymond James analyst Michael Freeman reiterated an Outperform rating and $14.00 price target on WAVE Life Sciences (NASDAQ: WVE).

Yun Zhong

Wedbush

$18

Buy

151.40%

Upside

Reiterated

09/03/25

Optimistic Buy Rating for Wave Life Sciences Driven by Promising RNA Editing Technology and Strong Safety Profile

Salim Syed

Mizuho Securities

$22

Buy

207.26%

Upside

Reiterated

08/04/25

Mizuho Securities Reaffirms Their Buy Rating on Wave Life Sciences (WVE)WVE (OP, maintaining PT at $22): No major changes to our model.

Cheng Li

Oppenheimer

$24

Buy

235.20%

Upside

Initiated

07/31/25

Wave Life Sciences initiated with an Outperform at OppenheimerWave Life Sciences initiated with an Outperform at Oppenheimer

Luca Issi

RBC Capital

Hold

25.70%

Upside

Reiterated

07/30/25

Analysts Offer Insights on Healthcare Companies: Dexcom (NASDAQ: DXCM), ADC Therapeutics (NYSE: ADCT) and Wave Life Sciences (NASDAQ: WVE)

Samantha Semenkow

Citi

$16

Buy

123.46%

Upside

Initiated

07/17/25

Wave Life Sciences: Promising RNA Therapies and Strong Financial Position Support Buy Rating

Steven Seedhouse

Cantor Fitzgerald

$10

Buy

39.66%

Upside

Reiterated

07/11/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Wave Life Sciences (WVE)

Roger Song

Jefferies

$26

Buy

263.13%

Upside

Reiterated

03/26/25

Jefferies reiterates Buy Rating on WAVE Life Sciences (WVE)Jefferies analyst Roger Song reiterated a Buy rating and $26.00 price target on WAVE Life Sciences (NASDAQ: WVE).

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Wave Life Sciences

1 Month

xxx

Success Rate

8/16 ratings generated profit

Average Return

+5.24%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +5.24% per trade.

3 Months

xxx

Success Rate

9/18 ratings generated profit

Average Return

+18.04%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +18.04% per trade.

1 Year

Andrew FeinH.C. Wainwright

Success Rate

10/16 ratings generated profit

Average Return

+23.88%

reiterated a buy rating 10 days ago

Copying Andrew Fein's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +23.88% per trade.

2 Years

xxx

Success Rate

10/16 ratings generated profit

Average Return

+14.54%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 62.50% of your transactions generating a profit, with an average return of +14.54% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

WVE Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, WVE has received 21 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. WVE average Analyst price target in the past 3 months is 18.23.

Each month's total comprises the sum of three months' worth of ratings.

WVE Financial Forecast

WVE Earnings Forecast

Next quarter’s earnings estimate for WVE is -$0.26 with a range of -$0.39 to $0.30. The previous quarter’s EPS was -$0.31. WVE beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 32.86% of the time in the same period. In the last calendar year WVE has Outperformed its overall industry.

WVE Sales Forecast

Next quarter’s sales forecast for WVE is $12.89M with a range of $0.00 to $40.00M. The previous quarter’s sales results were $8.70M. WVE beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 44.14% of the time in the same period. In the last calendar year WVE has Outperformed its overall industry.

WVE Stock Forecast FAQ

What is WVE’s average 12-month price target, according to analysts?

Based on analyst ratings, Wave Life Sciences’s 12-month average price target is 18.23.

What is WVE’s upside potential, based on the analysts’ average price target?

Wave Life Sciences has 154.61% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is WVE a Buy, Sell or Hold?

Wave Life Sciences has a consensus rating of Strong Buy which is based on 13 buy ratings, 1 hold ratings and 0 sell ratings.

What is Wave Life Sciences’s price target?

The average price target for Wave Life Sciences is 18.23. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $26.00 ,the lowest forecast is $9.00. The average price target represents 154.61% Increase from the current price of $7.16.

What do analysts say about Wave Life Sciences?

Wave Life Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of WVE?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Wave Life Sciences (WVE) Stock Forecast & Price Target

WVE Analyst Ratings

WVE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Wave Life Sciences

WVE Analyst Recommendation Trends

WVE Financial Forecast

WVE Earnings Forecast

WVE Sales Forecast

WVE Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts